Dextromethorphan/bupropion GudangMovies21 Rebahinxxi LK21

Dextromethorphan/bupropion (DXM/BUP), sold under the brand name Auvelity, is a combination medication for the treatment of major depressive disorder (MDD). Its active components are dextromethorphan (DXM) and bupropion. Patients who stayed on the medication had an average of 11% greater reduction in depressive symptoms than placebo in an FDA approval trial. It is taken as a tablet by mouth.
Side effects of dextromethorphan/bupropion include dizziness, headache, diarrhea, somnolence, dry mouth, sexual dysfunction, and hyperhidrosis, among others. The mechanism of action of dextromethorphan/bupropion in the treatment of depression is unknown.
Dextromethorphan/bupropion was developed by Axsome Therapeutics and was approved for the treatment of major depressive disorder in the United States in August 2022.




Medical uses






= Depression

=

Dextromethorphan/bupropion is approved for the treatment of major depressive disorder. Dextromethorphan and bupropion have both individually been reported to be effective for the treatment of this condition. The effect size of bupropion alone relative to placebo for depression is small, whereas only limited evidence exists for dextromethorphan alone. The combination was approved in the US on the basis of two regulatory clinical trials.
In Study 1 (GEMINI), a 6-week randomized controlled trial of dextromethorphan/bupropion versus placebo in people with major depressive disorder, scores on the Montgomery–Åsberg Depression Rating Scale (MADRS)—a scale with a range of 0 to 60 points—decreased with dextromethorphan/bupropion by 15.9 points from a baseline score of 33.6 points (an approximate 47% reduction) and decreased with placebo by 12.1 points from a baseline score of 33.2 points (an approximate 36% reduction). This resulted in a least-squares mean difference in reduction of depression scores between dextromethorphan/bupropion and placebo of 3.9 points, with the placebo group showing approximately 76% of the improvement in depression scores as the dextromethorphan/bupropion group and with depression scores at baseline improving overall about 11% more with the medication than with placebo. In antidepressant trials of 6 to 8 weeks duration recorded in the Food and Drug Administration (FDA) database, the average difference from placebo with other antidepressants was 2.5 points. The mean improvement in scores with dextromethorphan/bupropion was statistically significant but not clinically significant relative to placebo at all assessed timepoints including at the end of week 1, although at the end of the study some patients did have clinically significant improvement.
In Study 2 (STRIDE-1), dextromethorphan/bupropion was compared with bupropion alone in another randomized controlled trial. The dose of bupropion in the study was lower than the target dose recommended for clinical practice. In this study, dextromethorphan/bupropion showed significantly greater improvement than bupropion alone in the first two weeks of treatment but not by week 6 of treatment in people with major depressive disorder. The baseline scores were 33.4 points with dextromethorphan/placebo and 33.2 points with placebo, while the score reductions at week 1 were 5.2 points on the MADRS with dextromethorphan/bupropion and 3.6 points with bupropion (a 1.6-point difference), at week 2 were 8.0 points with dextromethorphan/bupropion and 6.1 points with bupropion (a 1.9-point difference), and at week 6 were 11.6 points with dextromethorphan/bupropion and 9.4 points with bupropion (a 2.2-point difference). On the basis of this trial, the FDA concluded that dextromethorphan contributes to the apparent antidepressant effects of dextromethorphan/bupropion.




Side effects


Side effects of dextromethorphan/bupropion include dizziness, nausea, headache, diarrhea, somnolence, dry mouth, sexual dysfunction (including abnormal orgasm, erectile dysfunction, decreased libido, and anorgasmia), hyperhidrosis, anxiety, constipation, decreased appetite, insomnia, arthralgia, fatigue, paresthesia, and blurred vision. These side effects occurred at rates ≥2% and to a greater extent than with placebo in clinical trials.




Pharmacology






= Pharmacodynamics

=
Dextromethorphan acts as an NMDA receptor antagonist, σ1 receptor agonist, and serotonin–norepinephrine reuptake inhibitor, among other actions, while bupropion acts as a norepinephrine–dopamine reuptake inhibitor and nicotinic acetylcholine receptor negative allosteric modulator. Bupropion is also a potent inhibitor of CYP2D6, and thereby inhibits the metabolism of dextromethorphan. Dextromethorphan/bupropion has less activity as an NMDA receptor antagonist than dextromethorphan alone. This is because bupropion is a potent CYP2D6 inhibitor and prevents the bioactivation of dextromethorphan into dextrorphan, a much more potent NMDA receptor antagonist and weaker serotonin reuptake inhibitor than dextromethorphan itself. The mechanism of action of dextromethorphan/bupropion in the treatment of depression is unknown, although the preceding pharmacological actions are assumed to be involved.




= Pharmacokinetics

=
When administered together as dextromethorphan/bupropion, the elimination half-life of dextromethorphan is 22 hours and the elimination half-life of bupropion is 15 hours. The elimination half-lives of bupropion active metabolites are 35 hours for hydroxybupropion, 44 hours for erythrohydrobupropion, and 33 hours for threohydrobupropion. Bupropion inhibits the metabolism of dextromethorphan by inhibiting the enzyme CYP2D6, the major enzyme responsible for the metabolism of dextromethorphan. This in turn improves the bioavailability of dextromethorphan, prolongs its half-life, prevents its metabolism into dextrorphan, and increases the ratio of dextromethorphan to dextrorphan in the body.




History


Dextromethorphan/bupropion was developed by Axsome Therapeutics. It was approved for the treatment of major depressive disorder by the US Food and Drug Administration in August 2022.




Society and culture






= Brand names

=
Dextromethorphan/bupropion is sold under the brand name Auvelity.




= Legal status

=
Dextromethorphan/bupropion is not a controlled substance in the United States. The misuse potential of dextromethorphan and bupropion has not been systematically studied. However, both dextromethorphan and bupropion may have misuse liability at supratherapeutic doses. Despite the known misuse potential of dextromethorphan, it is available widely as an over-the-counter drug. Conversely, bupropion is a prescription-only medication.




Research


Dextromethorphan/bupropion is under development for the treatment of agitation in Alzheimer's disease and smoking withdrawal. As of August 2022, it is in phase III clinical trials for agitation and phase II trials for smoking withdrawal.




References

Kata Kunci Pencarian:

• Antikolinergik
• Dextromethorphan/bupropion
• Dextromethorphan
• Bupropion
• Naltrexone/bupropion
• Dextromethorphan/quinidine
• Antidepressant
• List of antidepressants
• Sertraline
• Venlafaxine
• Norepinephrine reuptake inhibitor

Dextromethorphan/bupropion - Wikipedia

Bupropion / Dextromethorphan Dosage Guide + Max Dose, Adjustments ...

Clinical Data with Dextromethorphan-bupropion

Clinical Experience with Dextromethorphan-bupropion

Dextromethorphan-Bupropion in Depression

Bupropion - Mechanism of Action and Psychopharmacology

Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients ...

Auvelity for the Treatment of Major Depressive Disorder, US

Dextromethorphan-bupropion effective in improving symptoms of major ...

DEXTROMETHORPHAN HYDROBROMIDE 5MG+ CHLORPHENIRAMINE MALEATE 2MG(MYLIX)

DailyMed - BUPROPIDEX- dextromethorphan hydrobromide tablet

Dextromethorphan | WCTU

dextromethorphan bupropion

Daftar Isi

• Dextromethorphan/bupropion - Wikipedia
• Meet the newest antidepressant: dextromethorphan/buproprion
• Bupropion and dextromethorphan - Drugs.com
• Dextromethorphan and bupropion (oral route) - Mayo Clinic
• Dextromethorphan-bupropion (Auvelity) for the Treatment of …
• MEDICATION FACT SHEET Dextromethorphan and Bupropion
• Dextromethorphan-Bupropion in Depression - Psychiatric Times
• Dextromethorphan and Bupropion: MedlinePlus Drug Information
• Dextromethorphan and bupropion (Oral) - Drugs.com
• Dextromethorphan/Bupropion: A Novel Treatment for Patients

Dextromethorphan/bupropion - Wikipedia

Dextromethorphan/bupropion (DXM/BUP), sold under the brand name Auvelity, is a combination medication for the treatment of major depressive disorder (MDD). [1] Its active components are dextromethorphan (DXM) and bupropion. [1]

Meet the newest antidepressant: dextromethorphan/buproprion

Oct 24, 2022 · Until now, dextromethorphan has been best known as a cough suppressant, and bupropion is currently FDA-approved to treat major depressive disorder and to facilitate tobacco cessation.

Bupropion and dextromethorphan - Drugs.com

Oct 3, 2024 · Bupropion and dextromethorphan (brand Auvelity) is an antidepressant medicine used to treat major depressive disorder (MDD), which is a specific type of depression. Dextromethorphan and bupropion is a rapid-acting antidepressant that started working as early as 1 week, and patients' depression symptoms continued to improve over time when ...

Dextromethorphan and bupropion (oral route) - Mayo Clinic

Dextromethorphan and bupropion combination is used to treat major depressive disorder (MDD). This medicine is available only with your doctor's prescription.

Dextromethorphan-bupropion (Auvelity) for the Treatment of …

Dextromethorphan- bupropion combination tablet represents a novel rapid- acting oral treatment option for depression in adults. In this article, we describe the efficacy and safety of dextromethorphan-bupropion in the treatment of major depressive disorder in adults.

MEDICATION FACT SHEET Dextromethorphan and Bupropion

Dextromethorphan/bupropion should be taken once daily in the morning for the first 3 days of therapy; thereafter, it should be taken twice daily (with each dose given at least 8 hours). The typical dosing range is one tablet once or twice daily based on your kidney function.

Dextromethorphan-Bupropion in Depression - Psychiatric Times

Sep 25, 2022 · This study demonstrates that dextromethorphan-bupropion significantly improves depressive symptoms compared to bupropion and was generally well tolerated. This combination represents a novel pharmacologic approach to the treatment of MDD.

Dextromethorphan and Bupropion: MedlinePlus Drug Information

Dextromethorphan and bupropion is used to treat depression. Dextromethorphan is in a class of medications called NMDA receptor antagonists. The way it works in the brain to treat depression is not known. Bupropion is in a class of medications called antidepressants. It works by increasing certain types of activity in the brain.

Dextromethorphan and bupropion (Oral) - Drugs.com

Mar 26, 2024 · Detailed drug Information for Dextromethorphan and bupropion. Includes common brand names, drug descriptions, warnings, side effects and dosing information.

Dextromethorphan/Bupropion: A Novel Treatment for Patients

DEX is a noncompetitive N-methyl-d-aspartate receptor antagonist rapidly metabolized through the CYP450 2D6. BUP is an aminoketone and CYP2D6 inhibitor, which results in increased plasma levels of DEX through competitive CYP2D6 inhibition.